New Dosing Protocol May Shorten Fabrazyme Infusions

New Dosing Protocol May Shorten Fabrazyme Infusions

296493

New Dosing Protocol May Shorten Fabrazyme Infusions

A new infusion protocol that gradually reduces the amount of time needed for the delivery of the Fabry disease therapy Fabrazyme (algasidase beta) is safe and well-tolerated, a study reports. The study, “Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol,” was published in Molecular Genetics & Genomic Medicine. Fabrazyme, by Sanofi Genzyme, is an enzyme replacement therapy (ERT) for Fabry disease. It contains a version of the alpha-galactosidase A enzyme, which…

You must be logged in to read/download the full post.